


-55-

## CLAIMS

1. A compound of formula



or a pharmaceutically acceptable salt thereof,

5

or a prodrug thereof,

wherein n is an integer of from 1 to 4.

2. A compound according to Claim 1 wherein n is an integer of from 2 to 4.

3. A compound according to Claim 1 wherein the compound is a compound of Formula I.

10

4. A compound according to Claim 1 and selected from: add name for  
 (1 $\alpha$ ,6 $\alpha$ ,8 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid;  
 (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid; (2-Aminomethyl-  
 octahydro-pentalen-2-yl)-acetic acid; (2-Aminomethyl-octahydro-  
 pentalen-2-yl)-acetic acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic  
 acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; and  
 (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid.

15

5. A compound according to Claim 1 and selected from:  
 (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
 (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
 (1 $\alpha$ ,5 $\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
 (1 $\alpha$ ,6 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
 (1 $\alpha$ ,7 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,

20

- (1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
(1 $\alpha$ ,5 $\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
(1 $\alpha$ ,5 $\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
5 (1 $\alpha$ ,7 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
(1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\alpha$ ,8 $\alpha$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
(1 $\alpha$ ,7 $\alpha$ ,9 $\alpha$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
10 (1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
(1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
(1 $\alpha$ ,6 $\alpha$ ,8 $\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
(1 $\alpha$ ,7 $\alpha$ ,9 $\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
15 ((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
20 ((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((3 $\alpha$ R,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ R,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
25 ((3 $\alpha$ S,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((2R,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
30 ((2R,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,

-57-

- ((2R,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
5 ((2S,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2R,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
10 ((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
15 ((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
((3 $\alpha$ R,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ R,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((3 $\alpha$ S,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
20 ((3 $\alpha$ S,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
((2R,4 $\alpha$ R,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
((2R,4 $\alpha$ S,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
25 ((2R,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,  
((2S,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, and  
30

-58-

((2R,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid.

6. A compound according to Claim 1 named (1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid.
- 5 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
8. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in  
10 need of said treatment.
9. A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
10. A method for treating neurodegenerative disorders comprising  
15 administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
11. A method for treating depression comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 20 12. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
13. A method for treating panic comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in  
25 need of said treatment.

-59-

14. A method for treating pain comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 5 15. A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
16. A method for treating premenstrual syndrome comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.